Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07163065
Active, not recruiting Observational

Evaluation of Systemic Inflammatory Index and Biomarkers in Relation to Inferior Alveolar Nerve Block Success and Postoperative Pain

NCT07163065 · tracked via the Priya Life Science Turkey tracker
Sponsor
KEZBAN MELTEM ÇOLAK
Phase
Observational
Started
2024-09-27
Last updated
2025-09-09

Condition(s) studied

Postoperative PainInferior Alveolar Nerve Block FailureInflammation BiomarkersDental Anesthesia Complications

Investigational drug(s) / intervention(s)

Inferior Alveolar Nerve Block Anesthesia

Inferior Alveolar Nerve Block Anesthesia: Standard inferior alveolar nerve block anesthesia performed with lidocaine and epinephrine for mandibular dental treatment. Success rate and postoperative pain outcomes will be recorded

Study summary

This study aims to investigate the relationship between systemic inflammatory markers and the effectiveness of inferior alveolar nerve block anesthesia in patients undergoing dental treatment. The primary focus is on the Systemic Inflammatory Index (SII) and other inflammatory biomarkers, and how they may influence both the success of anesthesia and the intensity of postoperative pain. By analyzing blood samples and clinical outcomes, the study will provide new insights into the role of systemic inflammation in anesthesia effectiveness and postoperative pain control. The findings may help clinicians predict anesthetic success and improve pain management strategies in dental practice.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged between 18 and 65 years. Patients with a pain score greater than 54 on the Heft-Parker Visual Analog Scale (VAS). Patients classified as ASA I according to the American Society of Anesthesiologists (ASA). Teeth with probing depths less than 3 mm, suitable for rubber dam placement and restoration. Vital mandibular molar teeth with a clinical diagnosis of irreversible pulpitis, confirmed by pulp vitality tests (electric pulp testing and cold testing). Presence of bleeding upon access to the pulp chamber. No use of non-steroidal anti-inflammatory drugs (NSAIDs) within the last 12 hours. Absence of allergy to articaine. Patient's consent to provide a blood sample. Exclusion Criteria: * Patients classified as ASA II or higher. Pregnant women or those with suspected pregnancy. Patients with periodontal pockets greater than 3 mm in the involved tooth. Patients who received treatment with NSAIDs within the last 12 hours. Patients allergic to articaine. Teeth that had undergone previous endodontic treatment. Teeth with extensive structural loss preventing rubber dam isolation. Presence of internal or external root resorption.

Primary outcome measure(s)

  • Success Rate of Inferior Alveolar Nerve Block Anesthesia — Within 15 minutes after injection
    Proportion of patients achieving successful anesthesia, defined as absence of pain during dental treatment following inferior alveolar nerve block.

Trial sites (1)

FacilityCityRegionStatus
Atatürk University Faculty of Dentistry, Department of Endodontics Erzurum Erzurum

More KEZBAN MELTEM ÇOLAK trials in Turkey

Effect of Ozone Use in Intracanal Irrigation on Oxidative Stress Level in Teeth With Asymptomatic Apical Periodontitis Active, not recruiting
Effect Of Different Sodium Hypochlorite Concentrations On Intracanal Substance P, CGRP And Opiorphin Levels And Postoperative Pain During Root Canal Retreatment Recruiting

Other trials for the same condition

SPSIP vs ESP Block for Analgesia After Rib Fracture Surgery Starting soon
FRONT Block for Quality of Recovery After Total Hip Arthroplasty Recruiting
S-TAP vs RSB in Midline Abdominal Incision Laparotomy Active, not recruiting
Comparison of TAP Block and Umbilical Paramedian Linea Semilunaris Block in Pediatric Laparoscopic Surgery Starting soon
Serratus Posterior Superior Intercostal Plane Block in Minimally Invasive Cardiac Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07163065 on ClinicalTrials.gov ↗ ← All trials in Turkey